Back to Journals » Biologics: Targets and Therapy » Volume 6

Castration-resistant prostate cancer: potential targets and therapies

Authors Parray, Siddique HR, Nanda S, Konety BR, Saleem M

Received 28 June 2012

Accepted for publication 13 July 2012

Published 17 August 2012 Volume 2012:6 Pages 267—276


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Aijaz Parray,1 Hifzur R Siddique,1 Sanjeev Nanda,1,2 Badrinath R Konety,3 Mohammad Saleem1,3,4

Molecular Chemoprevention and Therapeutics, The Hormel Institute, University of Minnesota, Austin, 2Department of Internal Medicine, Mayo Clinic Health Systems, Austin, 3Department of Urology, University of Minnesota, Minneapolis, 4Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA

Abstract: The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.

Keywords: chemoresistance, CRPC, molecular pathways, neoplastic prostate

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]